MTAP Deficiency Creates an Exploitable Target for Antifolate Therapy in 9p21-Loss Cancers
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers
Nat Commun 2022 Apr 04;13(1)1797, O Alhalabi, J Chen, Y Zhang, Y Lu, Q Wang, S Ramachandran, RS Tidwell, G Han, X Yan, J Meng, R Wang, AG Hoang, WL Wang, J Song, L Lopez, A Andreev-Drakhlin, A Siefker-Radtke, X Zhang, WF Benedict, AY Shah, J Wang, P Msaouel, M Zhang, CC Guo, B Czerniak, C Behrens, L Soto, V Papadimitrakopoulou, J Lewis, W Rinsurongkawong, V Rinsurongkawong, J Lee, J Roth, S Swisher, I Wistuba, J Heymach, J Wang, MT Campbell, E Efstathiou, M Titus, CJ Logothetis, TH Ho, J Zhang, L Wang, J GaoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.